Morgan Stanley Infla Rx N.V. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Infla Rx N.V. stock. As of the latest transaction made, Morgan Stanley holds 668,131 shares of IFRX stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
668,131
Previous 827,831
19.29%
Holding current value
$1.17 Million
Previous $1.44 Million
29.03%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding IFRX
# of Institutions
29Shares Held
12.9MCall Options Held
19.3KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$10 Million0.35% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$3.62 Million0.29% of portfolio
-
Eversept Partners, LP New York, NY1.62MShares$2.84 Million0.2% of portfolio
-
Ubs Oconnor LLC Chicago, IL798KShares$1.4 Million0.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX705KShares$1.23 Million0.19% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $77.4M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...